Literature DB >> 1868488

In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

V Schirrmacher1, S Leidig, A Griesbach.   

Abstract

Tumour-specific cytotoxic T lymphocytes (CTL) are usually obtained after immunization in vivo and restimulation of immune cells in vitro. We here describe the generation of syngeneic tumour-specific CTL within no more than 9 days by priming and restimulation in vivo. This is achieved only if the correct sites are used both for primary immunization (ear pinna) and for restimulation (peritoneal cavity). The kinetics of immune T cell induction and of the secondary response in vivo will be reported. While a secondary CTL response could be generated in the peritoneal cavity, this was not possible in the spleen, no matter which routes of antigen restimulation were used. Upon transfer of immune spleen cells into the peritoneal cavity but not into the spleen, a secondary response could be generated upon in situ restimulation, indicating the importance of the correct microenvironment for this type of response. The peritoneal effector cells were true T cells and recognized a tumour-associated antigen in association with the Kd major histocompatibility (MHC class I) antigen. Finally the activated tumour-specific peritoneal exudate cells were able to transfer protective immunity without exogenous interleukin-2 into normal syngeneic mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868488     DOI: 10.1007/bf01756594

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

Review 1.  The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors.

Authors:  T A Springer
Journal:  Annu Rev Cell Biol       Date:  1990

2.  Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro.

Authors:  K Bosslet; V Schirrmacher; G Shantz
Journal:  Int J Cancer       Date:  1979-09-15       Impact factor: 7.396

3.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

4.  Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo.

Authors:  V Schirrmacher; G Shantz; K Clauer; D Komitowski; H P Zimmermann; M L Lohmann-Matthes
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

5.  Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis.

Authors:  V Schirrmacher
Journal:  Immunobiology       Date:  1980-07       Impact factor: 3.144

6.  Antibody 12-15 cross-reacts with mouse Fc gamma receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein.

Authors:  P Altevogt; U Kohl; P Von Hoegen; E Lang; V Schirrmacher
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity.

Authors:  E T Akporiaye; M Kudalore; A P Stevenson; P M Kraemer; C C Stewart
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

9.  Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.

Authors:  P Von Hoegen; E Weber; V Schirrmacher
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

10.  Rejection of ascites tumor allografts. I. Isolation, characterization, and in vitro reactivity of peritoneal lymphoid effector cells from BALB-c mice immune to EL4 leukosis.

Authors:  G Berke; K A Sullivan; B Amos
Journal:  J Exp Med       Date:  1972-06-01       Impact factor: 14.307

View more
  4 in total

1.  Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.

Authors:  Yolanda D Mahnke; Jochen Schwendemann; Philipp Beckhove; Volker Schirrmacher
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

Review 2.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

3.  Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection.

Authors:  K Khazaie; S Prifti; P Beckhove; A Griesbach; S Russell; M Collins; V Schirrmacher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

4.  Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Authors:  A Eisenthal; Y Skornick; O Merimsky; R Hirsch; V Zakut; I Ron; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.